Abstract
Epigenetics is a fast moving field and our understanding of epigenetic mechanisms has dramatically improved in recent decades. We present the role that epigenetics plays in genomic control in humans; the molecular basis of this control and the role that epigenetic aberrations play in the aetiology of human disease. We outline some of the laboratory techniques for characterising epigenetic variation from methylation analysis of a single CpG to characterising histone variation across extensive genomic regions. The fields of computational epigenetics and population epigenetics have recently emerged and we discuss developments in statistical methods that use DNA methylation as biomarker for the prediction of disease. Finally we describe how DNA methylation errors that occur during somatic cell divisions have been used as a molecular clock that allows inferences about cell population histories to be made.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Rollins RA, Haghighi F, Edwards JR, Das R, Zhang MQ, Ju J, Bestor TH. Large-scale structure of genome methylation patterns. Genome Res. 2006; 16:157–163.
Kim TH, Barrera LI, Zheng M, Qu C, Singer MA, Richmond TA, Wu Y, Green RD, Ren B. A high resolution map of active promoters in the human genome. Nature 2005; 436:876–880.
Liang G, Chan MF, Tomigahara Y, Tsai YC, Gonzales FA, Li E, Laird PW Jones PA. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol. Cell. Biol. 2002; 22:480–491.
Comb M and Goodman HM. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res. 1990; 18:3975–3982.
Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG- binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 2003; 278:4035–4040.
Yang XJ and Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996; 382:319–324.
Sun ZWand Allis CD. Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature 2002; 48:104–108.
Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V, Doderlein G, Maltry N, Wu W, Lyko F, Niehrs C. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007; 445:671–675.
Schwarz YB and Pirrotta V. Molecular mechanisms of polycomb silencing. In ‘Epigenetics’ edited by J. Tost; 2008, Caister Academic Press, Norfolk, England.
Chan C-S, Rastelli L, Pirrotta V. A polycomb response element in Ubx gene that determines an epigenetically inherited state of repression. EMBO J. 1994; 13:2553–2564.
Kassis JA. Pairing sensitive silencing, polycomb group response elements and transposon homing in Drosophila. Adv. Genet. 2002; 246:421–438.
Kahn TG, Schwartz YB, Dellino GI, Pirrotta V. Polycomb complexes and the propagation of the methylation mark at the Drosophila Ubx gene. J. Biol. Chem. 2006; 281:29064–29075.
Esteve Po, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, Carey MF, Pradharan S. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev. 2006; 20:3089–3103.
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa J-P, Markowitz JK, Willson JKV, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U.S.A. 1998; 95:96870–96875.
Iida T, Suetake I, Tajima S, Morioka H, Ohta S, Obuse C, Tsurimoto T. PCNA clamp facilitates action of DNA cytosine methyltransferase 1 on hemimethylated DNA. Genes Cells 2002; 7:997–1007.
Goyal R, Reinhardt R, Jeltsch A. Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase. Nucleic Acids Res. 2006; 34:1183–1188.
Margot JB, Cardaso MC, Leonhardt H. Mammalian DNA methyltransferases show different subnuclear distributions. J. Cell. Biochem. 2001; 83:373–379.
Jair K-W, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW-C, Baylin SB, Schuebel KE. De novo CpG island methylation in human cancer cells. Cancer Res. 2006; 66:682–692.
Chan TL, Yuen St, LKong Ck, Chan YW, Chan YS, Ng WF, Tsui WY, Lo MW, Tam WY, Li VS, Leung SY. Heritable germline epimutations of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet. 2006; 38:1178–1183.
Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, Wood WG, Higgs DR. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat. Gent. 2003; 34:157–165.
Bjornsson HT, Sigurdsson MI, Fallin MD, Irizarry RA, Aspelund T, Cui H, Yu W, Rongione MA, Ekström TJ, Harris TB, Launer LJ, Eiriksdottir G, Leppert MF, Sapienza C, Gudnason V, Feinberg AP. Intra-individual change over time in DNA methylation with familial clustering. JAMA 2008; 24:2877–2883.
Kaminsky ZA, Tang T, Wang SC, Ptak C, Oh GHT, Wong AHC, Feldcamp LA, Virtanen C, Halfvarson J, Tysk C, McRae AF, Visscher PM, Montgomery GW, Gottesman II, Martin NG, Petronis A. DNA methylation profiles in monozygotic and dizygotic twins. Nat. Genet. 2009; 41:240–245.
Chen C, Yang MC, Yang TP. Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites. J. Biol. Chem. 2001; 276:320–328.
Cameron EE, Baylin SB, Herman JG. P15iINK4B CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 1999; 94:2445–2451.
Jones PA and Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002; 3:415–428.
Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC, Catto JWF. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 2007; 13:2046–2053.
Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 2008; 75:145–151.
Marsit CJ, Kim DH, Liu M, Hinds PW, Wiencke JK, Nelson HH, Kelsey KT. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. Int J Cancer 2005; 114:219–223.
Du Y, Carling T, Fang W, Piao JZ, Sheu JC, Huang S. Hypermethylation in human cancers of the RIZ1 tumour suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. 2001; 61:8094–8099.
Catto JWF, Azzouzi AR, Rehman I, Feeley KM, Cross S, Amira N, Fromont G, Sibnony M, Cussenot O, Meuth M, Hamdy FC. Promoter hypermethylation is associated with tumour location stage and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 2005; 23:2903–2910.
Chen J, Röcken C, Lofton-Day C, Schulz HU, Müller O, Kutzner N, Malfertheiner P, Ebert MPA. Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis 2005; 26:37–43.
Handa V and Jeltsch A. Profound flanking sequence preference of Dnmt3a and Dnmt3b mammalian DNA methyltransferases shape the human epigenome. J. Mol. Biol. 2005; 348:1103–1112.
Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. DNA motifs associated with aberrant CpG island methylation. Genomics 2006; 87:572–579.
Ohm J, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwin T, Pruitt K, Sharkis SJ, Watkins ND, Hermann JG, Baylin SB. A stem cell-like chromatin pattern may predispose tumour suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007; 39(2):237–242.
Issa JP. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004; 4:988–993.
Ushijima T, Watanabe N, Shimizu K, Miyamoto K, Sugimura T, Kaneda A. Decreased fidelity in repeating CPG methylation patterns in cancer cells. Cancer Res. 2005; 65:11–17.
Grady WM, Willis J, Guildford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. Genet. 2000; 26:16–17.
Hermann JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa J-P, Markowitz S, Wilson JK, Hamilton Sr, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermathylation in colerectal carcinomas. Proc. Natl. Acad. Sci. USA 1998; 95:6870-6875.
Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295:1079–1082.
Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 2005; 435:745–746.
Mockler TC, Chan S, Sundaresan A, Chen H, Jacobsen SE, Ecker JR. Applications of DNA tiling arrays for whole-genome analysis. Genomics 2005; 85:1–15.
Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 1999; 59:3899–3903.
Laird CD, Pleasant ND, Clark AD, Sneeden JL, Hassan KM, Manley NC, Vary JC Jr, Morgan T, Hansen RS, Stöger R. Hairpin-bisulfite PCR: assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. Proc. Natl. Acad. Sci. U.S.A. 2004; 101:204–209.
Lauchenbruch PA. Analysis of data with an excess of zeros. Stat Methods Med Res 2002; 11:297–302.
Neuhauser M, Boes T, Jockel K-H. Two-part permutation tests for DNA methylation and microarray data. BMC Bioinformatics 2005; 6:35.
Virmani AK, Tsou JA, Siegmund KD, Shen LYC, Long TI, Laird PW, Gazdar AF, Laird-Offringa IA. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol. Biomarkers Prev. 2002; 11:291–297.
Model F, Adorjan P, Olek A, Piepenbrock C. Feature selection for DNA methylation based cancer classification. Bioinformatics 2001; 17:S157–S164.
Catto JWF, Linkens D, Abbod MF, Chen M, Burton JL, Feeley KM, Hamdy FC. Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modelling and artificial neural networks. Clin. Cancer Res. 2003; 9:4172–4177.
Siegmund KD, Laird PW, Laird-Offringa IA. A comparison of cluster analysis methods using DNA methylation data. Bioinformatics 2004; 20:1896–1904.
Marjoram P, Chang J, Laird PW, Siegmund KD. Cluster analysis for DNA methylation profiles having a detection threshold. BMC Bioinformatics 2006; 7:361.
Brena RM, Huang THM, Plass C. Toward a human epigenome. Nat. Genet. 2006; 38:1359–1360.
Yatabe Y, Tavare S, Shibata D. Investigating stem cells in human colon by using methylation patterns. Proc. Natl. Acad. Sci. U.S.A. 2001; 98:10839–10844.
Walters K. Colonic stem cell data is consistent with the immortal model of stem cell division under non-random strand segregation. Cell Prolif. 2009; 42:339–347.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Walters, K. (2011). Epigenetic Variation. In: Teare, M. (eds) Genetic Epidemiology. Methods in Molecular Biology, vol 713. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-416-6_14
Download citation
DOI: https://doi.org/10.1007/978-1-60327-416-6_14
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-415-9
Online ISBN: 978-1-60327-416-6
eBook Packages: Springer Protocols